Clinical efficacy of herbal coded formulation (Hypoff) as treatment of essential hypertension was investigated. Hypoff was found to be an economical, safe and effective drug for essential hypertension treatment and was statistically significant at P0.03.
Clinical efficacy of herbal coded formulation (Hypoff) as treatment of essential hypertension was investigated. Hypoff was found to be an economical, safe and effective drug for essential hypertension treatment and was statistically significant at P0.03.
Clinical efficacy of herbal coded formulation (Hypoff) as treatment of essential hypertension was investigated. Hypoff was found to be an economical, safe and effective drug for essential hypertension treatment and was statistically significant at P0.03.
Clinical efficacy of herbal coded formulation (Hypoff) as treatment of essential hypertension was investigated. Hypoff was found to be an economical, safe and effective drug for essential hypertension treatment and was statistically significant at P0.03.
Journal of Medicinal Plants Research Vol. 6(xx), pp.
xxx-xxx 23 April, 2012
Available online at http://www.academicjournals.org/JMPR DOI: 10.5897/JMPR11.xxxxx12-025 ISSN 1996-0875 2012 Academic Journals
Full Length Research Paper
Clinical evaluation of herbal medicine for essential hypertension
Muhammad Naseem Qasmi, Khan Usmanghani, Abdul Hannan, Halima Nazar, Shahab Uddin, E. Mohiuddin and M. Akram
Faculty of Eastern Medicine, Hamdard University, Karachi, Pakistan.
Accepted 27 January 2012
In the present study, clinical efficacy of herbal coded formulation (Hypoff) as treatment of essential hypertension was investigated. This was case control multicenter prospective randomized authentic allopathic control clinical trial. Open randomized descriptive study was employed in this study. The drug Hypoff was prescribed to test group while Captopril was prescribed to control group who were registered at Qasmi Clinic located at Orangi Town, North Nazimabad and Gulshan-e-Iqbal at Karachi. They all belong to urban population of Karachi. The age range of patients was 25 to 70 years. The response of the treatment on symptomatology of essential hypertension was analysed. Hypoff was found to be an economical, safe and effective drug for essential hypertension treatment and was statistically significant at P<0.03.
Population studies suggested blood pressure (BP) is a continuous variable, with no line of demarcation between normal and abnormal values (Kannel, 1996; Collins et al, 1990). As such, high blood pressure is, therefore, inferred as a leading risk factor for heart ailment, stroke, and kidney failure. This correlation is more robust with systolic than with diastolic BP. Even when BP is lowered by antihypertensive drugs, the associated reduction in the incidence of coronary heart ailments lags behind that of stroke (Laragh and Blumenfeld., 2000; Reaven et al., 1996; Higashi et al., 1997; Campese et al., 1996; Barba et al., 1996). In present study, coded herbal formulation Hypoff was evaluated for treatment of hypertension. This formulation comprises of Dorema ammoniacum, Nepeta hindostana, Rauwolfia serpentina, Valeriana officinalis and Bombyx mori, and the literature search are delineated herewith. This is case control directed multicentre prospective analysis evidence based assessment research work conducted at Qasmi Clinic located at Orangi Town, North Nazimabad and Gulshan-e-Iqbal at Karachi, on patients residing in the urban population.
*Corresponding author. E-mail: makram_0451@hotmail.com. MATERIAL AND METHODS
Selection criteria of male and female patients aged 25-70 year with essential hypertension with sitting DBP 90 and >140mm Hg were included in this study. The test group patients were prescribed unani formulation Hypoff which comprises of different herbal crude drug. The control groups were administered allopathic drug Captopril. The patients included in the trial were those reporting to the Outpatient Department. They were thoroughly examined for clinical signs and symptoms. Their blood pressure and pulse rates were recorded. Patients with all grades of hypertension, that was either newly detected or resistant to previous drug therapy were informed about the trial and were enrolled after signing a consent form. A chest film, ECG, fundoscopy and serum sodium, potassium, creatinine, cholesterol, SGOT, glucose, haemoglobin, total WBC count and urine analysis were performed. Patients with satisfactory results for these studies were considered for drug therapy. Patients with recent history of myocardial ischaemia, congestive cardiac failure, left ventricular failure, renal failure or cerebrovascular accidents were excluded from the study. Sixty patients (aged 18-65 years) were randomized to receive Hypoff (Dorema ammoniacum = 3 g, Nepeta hindostana= 3 g, Rauwolfia serpentina= 2 g, Valeriana officinalis= 3 g and Bombyx mori= 5 g) in the double-blind, parallel group trial. Then the patients received either 800 mg capsule = 0 size capsule, two capsule twice a day BID equally divided doses for one to three month. Selection of doses was on the basis of our clinical practice and doses were adjusted whenever necessary. Blood pressure and pulse rate were recorded in the supine position by the same physician / Hakim at the same time of the day at weekly intervals, using the same sphygmomanometer. The mean of three
readings was noted. At the end of 4 weeks of drug therapy, chest X-ray, ECG and laboratory investigations were repeated, drug therapy was tapered off and patients numbers were decoded. Results are expressed as mean SEM. A patient was categorized as a responder if his or her diastolic blood pressure at the end of the study period was less than 95 mmHg (accepted by WHO) or if there was a fall of 20 mmHg or more in diastolic blood pressure as compared to the initial value. For comparison of the antihypertensive activity of these 2 agents, reduction in diastolic B. P. from 0 to 4 weeks was calculated as the area under the curve (AUC) using the trapezoidal rule. For statistical analysis, the Chi square and Fishers exact test were carried out. All differences were considered statistically significant by generating a p-value from test statistics. The significant result with p-value less than 0.05 was defined as statistically significant.
Inclusion criteria
The cases suffering from moderate to mild hypertension were selected on the following lines.
Patients between age group of 25 to 70 years. Patient having no obvious pathological findings on routine examination. Patients living in Karachi, Pakistan. All socio-economical classes including lower, middle and upper.
Exclusion criteria
The cases were excluded on the following lines.
Patient with concurrent physical illness, for example, uncontrolled diabetes and diabetic nephropathy. Patient with hepatic or renal impairment. Patient belonging to area outside Karachi because of inherent difficulty in follow up. Pregnant women. History of myocardial ischaemia Congestive cardiac failure Left ventricular failure Renal failure or cerebrovascular accidents were excluded from the study.
Sample size
Sample size estimation in this clinical study has been done based on general physical examination, general appearance of the patients, age, sex, and local examination of the blood pressure measurement in a pilot study at Qasmi Matabs. This pilot study included 100 cases each administered with herbal as test drug and allopathic medicine as control.
Sample selection
The sample was selected from the outpatient enrolled in Qasmi Matab and on the basis of preliminary clinical examination, the patients who were suffering from blood pressure were referred to the project Hakim and upon the basis of inclusion and exclusion criteria, the patient mashed as candidate were selected. The study period include 2 years time from 2007 to 2009. Among this population, the entire patients suffering from hypertension were interviewed immediately and upon their consent to participate they were grouped as case and control group.
Data collection
Data collected for this study included filling questionnaire through personal interview, personal observation, use of case record, file and documents. The clinical trial proforma attached here which clearly specifies the clinical feature and information. Calculations were carried out using the following formulas:
Class interval = 1 + 3.3 log(n)
Range = largest observation Smallest observation
Class size = Range/Class Interval
Statistical analysis
Statistical analysis were performed using SPSS in cooperation with Mr. Syed Tashfeen Akhter, Assistant Manager, Takaful Pakistan Limited, using excel software, the Chi square and the Fishers exact test. All differences were considered statistically significant by generating a p-value from test statistics. The significant result with p-value less than 0.05 was defined as statistically significant.
Study limitations
The data was adjusted based on the number of cases in the light of demographic factor using statistical methods like multinomial logistic regression. The data were composed in separate group. The groups were compared after random selection of subject in equal proportion using SPSS software. The subjects were divided into two groups, the case and the control groups. Finally, comparison was carried out between the case and control groups separately.
Ethical issues
Ethical committee clearance and permission was obtained whenever necessary considering the followings:
Informing each participant of the study and interviewing and examining the patient who consented to participate in the study. Identity will not be revealed and the data would be kept strictly confidential. Copy of the entire data will be made available to the Shifa ul Mulk Memorial Hospital.
RESULT AND DISCUSSION
This study was under taken as an observational paradigm in which an attempt was made to explore the essential hypertension patients with herbal and allopathic medicine so as to asses their efficacy. The diagnosis of essential hypertension was established by detecting elevated blood pressure more than 140/90 mm Hg by sphygmomanometer measurement on three different occasions within two weeks and the standard clinical trial proforma was filled for registration. Different parameters, that is, age, sex, duration, blood pressure, and other clinical sign and symptoms base line were studied and compared between two groups at base line and end of therapeutic applications. All these data were analyzed
Table 1. Mean distribution by treatment group.
Treatment group Mean Number (n) Std. deviation Test drug (Hypoff) Male 46.76 33 13.328 Female 41.00 17 9.260 Total 44.80 50 12.312 Control drug (Captopril) Male 39.86 28 10.693 Female 42.05 22 10.887 Total 40.82 50 10.724 Total Male 43.59 61 12.578 Female 41.59 39 10.094 Total 42.81 100 11.660
Table 2. Distribution of age group in total patients.
Age group (Years) Treatment group Total (n) Test (n) Control (n) 25 30 3 8 11 31 36 12 9 21 37 42 13 18 31 43 48 6 4 10 49 54 3 1 4 55 60 4 9 13 61 66 6 0 6 67 72 3 1 4 Total 50 50 100
by Chi-Square and the level of significance were applied. A comparative study was conducted for Hypoff with Captopril. The present study was undertaken to evaluate the therapeutic efficacy of these medicine for essential Hypertension. The therapeutic evaluations of these medicines were conducted on 100 clinically diagnosed cases of Hypertension at Matab Qasmi Clinic located at Orangi Town, North Nazimabad and Gulshan-e-Iqbal in Karachi, on patients residing in the urban populace. These data was collected in the years from February, 2007 February, 2009 which completed the clinical trial protocol at baseline. Form the collected data of 100 patients enrolled into the study, 61 (61%) and 39 (39%) were male and female patients, respectively. These 100 patients have been selected out of 140 patients not only according to exclusion and inclusion criteria. Table 1 shows that there is no significant difference between the mean of age of the all patients, which are assigned for Hypoff as well as allopathic Captopril. The patients gender, age, and baseline clinical features at the time of enrolment were recorded in both treatment arms. So overall, 100 patients were selected and 50 patients assigned to (50%) herbal coded formulation (Hypoff) and 50 patients (50%) for allopathic Captopril. The age distribution of over all patients for Hypoff and Captopril are shown in Table 2.
Conclusion
This prospective study has clearly shown the benefits of initiating treatment with unani medicine and that, both the test and control drug was associated with higher blood pressure and greater reduction in both systolic and diastolic blood pressure from the base line. In conclusion, therapies resulted in early improved blood pressure with tolerability as compared with starting treatment with the dosage form design for patient with essential hypertension. The study was not designed to demonstrate complete treatment strategy approach for hypoff based regiven, but in primary care setting, if captopril exhibit adverse reaction, then hypoff could be used in a tapering fashion, thereby improving blood control rates for patients with primary essential hypertension. A significant portion of hypertension patients receiving conventional treatment can also use unani therapy for essential hypertension. Physician need to be aware of this practice, understand the rationale of this health
Hypertension
Sign and symptoms After applying test of significance with chi square p-value (P<0.05) Headache At base line No significant difference between test and control groups 0.351 After treatment No significant difference between test and control drugs 0.177 General weakness At base line No significant difference between test and control groups 0.161 After treatment Significant difference between test and control drugs 0.003 Irregular beat At base line No significant difference between test and control groups 0.305 After treatment Significant difference between test and control drugs 0.008 Essential hypertension At base line No significant difference between test and control groups 1 After treatment Significant difference between test and control drugs 0.026
seeking behavior, proactively enquire about their use and counsel patients regarding some of these therapies for adverse reactions and drug interactions.
REFERENCES
Kannel WB (1996). Blood pressure as a cardiovascular risk factor: Prevention and treatment. JAMA., 275: 1571-1576. Collins R, Peto R, MacMohan S (1990). Blood pressure, stroke and coronary artery disease: Overview of randomized drug trials in their epidemiological context. Lancet. 335: 827-839. Laragh JH, Blumenfeld JB (2000). Essential hypertension. In Brenner and Rectors The Kidney, Vol. II 6th ed. Philadelphia : WB Saunders. Pp. 1967-2000. Reaven GM, Lithell H, Landsberg L (1996). Hypertension and associated metabolic abnormalities the role of insulin resistance and the sympathoadrenal system. NEJM; 334: 374-81.
Higashi Y, Oshima T, Sasaki N (1997). Relationship between insulin resistance and endothelium dependent vascular relaxation in patients with essential hypertension. Hypertension. 29: 280-285. Campese VM, Tawadrous M, Bigazzi R (1996). Salt intake and plasma arterial natriuretic peptide and nitric oxide in hypertension. Hypertension. 28: 335-3340. Barba G, Cappuccio FP, Russ L (1996) et al. Renal function and blood pressure response to dietary salt restriction in normotensive men. Hypertension. 27: 1160-1164.